Patents Assigned to The Administrators of the Tulane Educational Fund
  • Patent number: 11217435
    Abstract: Provided are synthetic dendrimer calibrants for mass spectrometry. The calibrants are distinguished by their relative case and rapidity of synthesis, comparatively low cost, long shelf life, high purity, and amenability to batch synthesis as mixtures. The latter characteristic enables parallel preparation of higher molecular weight compounds displaying useful distributions of discrete molecular weights, thereby providing multi-point mass spectrometry calibration standards. Methods of making, tuning and using said calibrants are provided.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 4, 2022
    Assignee: The Administrators of the Tulane Educational Fund
    Inventor: Scott Grayson
  • Publication number: 20210401984
    Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are trasfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IF?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
    Type: Application
    Filed: September 17, 2021
    Publication date: December 30, 2021
    Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Robert Francis GARRY, Luis Manuel BRANCO, Bruce Alan BUNNELL, Russell B. WILSON, Samuel E. HOPKINS
  • Patent number: 11186917
    Abstract: Disclosed herein are precursor compounds, composite electrodes comprising the same, and methods of making and use thereof.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: November 30, 2021
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Pravin Shinde, James Donahue, Patricia R. Fontenot, Arunava Gupta, Shanlin Pan
  • Patent number: 11149068
    Abstract: Described herein are membrane permeabilizing peptides, polynucelotides encoding the peptides, and lipid vesicles comprising the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and lipid vesicles for research, diagnosis, disease prevention, and therapeutic treatment.
    Type: Grant
    Filed: December 24, 2018
    Date of Patent: October 19, 2021
    Assignees: The Administrator of the Tulane Educational Fund, The John Hopkins University
    Inventors: William C. Wimley, Gregory Wiedman, Kalina Hristova, Sarah Y. Kim
  • Patent number: 11123433
    Abstract: A variety of hydrophobically modified polypeptoids are provided. The hydrophobically modified polypeptoids can include a polyamide backbone having a random copolymer of two or more different types of repeat units, where one or more of the repeat units have nitrogen atom having a hydrophobic substituent attached thereto. Methods of making the hydrophobically modified polypeptoids are also provided, as well as uses of the hydrophobically modified polypeptoids, for example in liposomal drug delivery.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: September 21, 2021
    Assignees: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Donghui Zhang, Vijay John, Yueheng Zhang, Sunting Xuan
  • Patent number: 11123427
    Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are transfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 21, 2021
    Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
  • Patent number: 11121278
    Abstract: The use of photovoltaic (PV) cells to convert solar energy to electricity is becoming increasingly prevalent; however, there are still significant limitations associated with the widespread adoption of PV cells for electricity needs. There is a clear need for a high efficiency solar power system that supplies electricity at a competitive cost and that provides for an on-demand supply of electricity as well as energy storage. By combining aspects of concentrated solar power and concentrated photovoltaics, the present invention provides a device that enables the conversion of sunlight to electricity at very high efficiencies and that enables the transmission of thermal energy to heat storage devices for later use. The disclosed device enables transmissive CPV through the use of a multijunction PV cell mounted on a transparent base. The use of a multijunction cell allows for highly efficient absorption of light above the bandgap of the lowest bandgap subcell.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: September 14, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Matthew David Escarra, Benjamin Lewson, Yaping Ji, Qi Xu, Adam Ollanik
  • Patent number: 11106980
    Abstract: Embodiments herein implement quantum annealing with a driver Hamiltonian that uses oscillating fields to advantageously obtain a quantum speedup over classical computing techniques. For a many-body quantum system formed with qubits, the oscillating fields drive the qubits so as to independently modulate the magnitudes and/or directions of transverse terms of the driver Hamiltonian. In particular, embodiments provide a quantum speedup for two types of first-order phase transitions: the paramagnet-to-spin-glass transition, and transitions between distinct “bit string” states. The resulting speedup is robust against energy fluctuations (e.g., 1/f noise), in contrast to other strategies like variable-rate annealing. Each oscillating field may be an oscillating electric field or magnetic field. The oscillating fields can be implemented with superconducting flux qubits by coupling oscillating fluxes and/or voltages to the flux qubits.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: August 31, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventor: Eliot Kapit
  • Patent number: 11098053
    Abstract: Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: August 24, 2021
    Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: Amy Strong, Stephen Boue, Matthew Burow, Bruce Bunnell, Quan Jiang, Shilong Zheng, Guangdi Wang
  • Patent number: 11045427
    Abstract: The present invention discloses the morphology of hollow, double-shelled submicrometer particles generated through a rapid aerosol-based process. The inner shell is an essentially hydrophobic carbon layer of nanoscale dimension (5-20 nm), and the outer shell is a hydrophilic silica layer of approximately 5-40 nm, with the shell thickness being a function of the particle size. The particles are synthesized by exploiting concepts of salt bridging to lock in a surfactant (CTAB) and carbon precursors together with iron species in the interior of a droplet. This deliberate negation of surfactant templating allows a silica shell to form extremely rapidly, sealing in the organic species in the particle interior. Subsequent pyrolysis results in a buildup of internal pressure, forcing carbonaceous species against the silica wall to form an inner shell of carbon. The incorporation of magnetic iron oxide into the shells opens up applications in external stimuli-responsive nanomaterials.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: June 29, 2021
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Vijay John, Gary McPherson
  • Publication number: 20210187064
    Abstract: The invention provides compositions and methods for reducing symptoms of inflammation by administering therapeutically effective amounts of (a) (1) enterotoxic E. coli heat labile detoxified toxin A subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or (2) A1 subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or both (1) and (2), and (b) a carrier that causes internalization of the A subunit or A1 subunit, or both, into cells.
    Type: Application
    Filed: May 7, 2019
    Publication date: June 24, 2021
    Applicant: Administrators of the Tulane Educational Fund
    Inventors: Elizabeth Bray NORTON, John David CLEMENTS
  • Patent number: 11029303
    Abstract: The invention is directed to antibody compositions that specifically bind to polycyclic aromatic hydrocarbons (PAHs) and kits encompassing the same.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: June 8, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Diane Blake, Yue Sun
  • Publication number: 20210162033
    Abstract: Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be 5 used as adjuvants in compositions and methods to potentiate the immune response to immunogens.
    Type: Application
    Filed: April 10, 2019
    Publication date: June 3, 2021
    Applicant: Administrators of the Tulane Educational Fund
    Inventors: Lisa Ann MORICI, James B. McLACHLAN, Christopher J.H. DAVITT, Jonathan R. KURTZ
  • Patent number: 11009514
    Abstract: Disclosed are methods of, and assay and kits for, detecting and diagnosing methods of detecting, diagnosing, vulnerable carotid artery disease capable of becoming acutely symptomatic using the levels of Resolvin D1 (RvD1), docosahexaenoic acid (DHA), and arachidonic acid (AA). Also disclosed are methods of treating carotid artery disease and methods of identifying agents for use in the treatment of carotid artery disease.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: May 18, 2021
    Assignees: OCHSNER HEALTH SYSTEM, THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURE AND MECHANICAL COLLEGE, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Hernan A. Bazan, Yan Lu, Song Hong, Zhide Fang, Bokkyoo Jun, Thomas C. Woods
  • Patent number: 10956267
    Abstract: Error-transparent quantum gates may be implemented with one or two logical qubits, each having a plurality of coupled physical qubits. Error-transparent quantum gates implement Hamiltonians that commute with the Hamiltonian for single errors in the logical qubits, and thus can operate successfully even in the presence of single errors. As a result, error-transparent quantum gates may operate with higher fidelity than their error-opaque counterparts. Each of the logical qubits may be, for example, a very small logical qubit (VSLQ) formed from a cluster of transmons or other superconducting qubits.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: March 23, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventor: Eliot Kapit
  • Patent number: 10940646
    Abstract: A three dimensional (3D) printing system includes computer-executable instructions for obtaining a volumetric object representation file, parsing the volumetric object representation file into multiple layers, and for each layer, decomposing the layer into a sequence of continuous paths, aggregating non-continuous sets of tool paths with a single outer path and zero or more open or closed inner paths into islands, and generating one or more motion segments according to each island. Once generated, the motion segments may be aggregated to form a toolpath, which is used by the three dimensional printer to print a 3D model.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: March 9, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Sam Lensgraf, Ramgopal Mettu
  • Patent number: 10935542
    Abstract: Variations in the differentiation and lineage potential of stem cells, including mesenchymal stem cells, currently limit their therapeutic use. The ability to identify, isolate, and specifically amplify stem cell populations with desired differentiation potential would contribute the use of stem cells in research and therapy. The present invention discloses a method of assessing differentiation potential of stem cells by measuring the differential expression of antigens CD 146 and NG2 on the stem cells. The correlation between CD 146 and NG2 expression and differentiation and trilineage potential is explored. The invention also discloses methods to specifically amplify or enrich stem cells with desired differentiation potential, monitor the differentiation potential of a heterogeneous stem cell population, quantify the heterogeneity in differentiation potential of a stem cell culture, and remove stem cells with specific differentiation potentials from a heterogeneous cell culture.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: March 2, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND OFFICE OF TECHNOLOGY TRANSFER AND INTELLECTUAL PROPERTY DEVELOPMENT
    Inventors: Kim O'Connor, Katie Russell
  • Patent number: 10927250
    Abstract: Disclosed herein are amphiphilic surfactants which comprise a polymer chain having a hydrophobic unit and hydrophilic unit wherein the polymer is tethered to an inorganic nanoparticle. Further disclosed are methods for preparing the disclosed amphiphilic surfactants.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: February 23, 2021
    Assignee: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Scott Grayson, Alina Alb, Muhammad Ejaz
  • Patent number: 10919939
    Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: February 16, 2021
    Assignees: The Administrators of the Tulane Educational Fund, United States Department of Veterans Affairs
    Inventors: James E. Zadina, Laszlo Hackler
  • Patent number: 10918672
    Abstract: A method of curing (or at least treating) HIV, by obtaining small tissue mesenchymal stem cells (stMSC) from adipose tissue of a patient with HIV or from a syngeneic donor or an immuno-compatible donor, wherein said stMSC are i) 4-6 ?m in diameter, ii) pluripotent, and iii) have CD11b?, CD34?, CD45?, CD 29, CD 49, Oct 4 and SSEA 4 surface markers when harvested. Preferred sources are autologous adipose tissue. Next those stMSCs are gene edited to provide CCR5? stMSCs and optionally amplified by growth in culture and/or by cell selection for gene edited stMSCs and then re-introducing into the patient. Preferably, the CCR5? stMSCs will re-populate the patient with stem cells that can no longer act as latent HIV reservoirs and can differentiate into immune cells that are HIV resistant. If desired, the patient can be first treated, e.g., by radiation, to destroy the bone marrow cells before the re-introduction.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 16, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Stephen E. Braun, Reza Izadpanah, Eckhard Alt